Progress in heavy ion cancer therapy at IMP and future development

Author:

Li Qiang1234,Liu Xinguo1234,Dai Zhongying1234,He Pengbo1234,Ma Yuanyuan1234,Shen Guosheng1234,Jin Xiaodong1234,Ye Fei1234,Zheng Xiaogang1234,Zhao Ting1234,Zhang Hui1234,Li Zheng5,Zou Bingwen5,Pu Yuehu6,Chen Weiqiang1234

Affiliation:

1. Institute of Modern Physics Chinese Academy of Sciences Lanzhou Gansu China

2. Key Laboratory of Heavy Ion Radiation Biology and Medicine of Chinese Academy of Sciences Lanzhou Gansu China

3. Gansu Provincial Key Laboratory of Basic Research on Heavy Ion Radiation Application in Medicine Lanzhou Gansu China

4. University of Chinese Academy of Sciences Beijing China

5. Division of Thoracic Tumor Multimodality Treatment and Department of Radiation Oncology, Cancer Center, West China Hospital Sichuan University Chengdu Sichuan China

6. Medical Equipment Innovation Research Center, West China Hospital Sichuan University Chengdu Sichuan China

Abstract

AbstractBasic research on heavy ion cancer therapy such as radiobiology, medical physics, and therapeutic technique has been conducted at the Institute of Modern Physics (IMP), Chinese Academy of Sciences since 1995. Based on the achievements acquired in the basic research and the requirements for a heavy ion accelerator for radiotherapy purposes, a dedicated heavy ion therapy facility named Heavy Ion Medical Machine (HIMM) was designed at IMP and constructed in Wuwei, China. The HIMM facility consists of two electron cyclotron resonance ion sources, one cyclotron as the injector and one synchrotron as the main accelerator, and four different treatment rooms equipped with passive or active beam delivery systems, and accelerates carbon ions up to 400 MeV/u. After the performance inspection of HIMM organized by the National Medical Device Inspection Center, preclinical tests like cell and animal radiobiological experiments and dosimetric verification using anthropomorphic phantoms for elucidating the biophysical properties of the carbon ion beams provided by HIMM were carried out. According to the Chinese medical device regulations, a clinical trial in which 46 tumor patients were recruited and two hospitals participated was conducted in the HIMM facility, aiming at evaluating the treatment safety and short‐term efficacy of the medical device. The success of the clinical trial helped the HIMM facility be authorized by the Chinese government as a class III medical device. In this paper, all the aspects mentioned above are introduced and discussed, and implications for future improvements are also given.

Publisher

Wiley

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3